An investigation for investors in NASDAQ:AMAG shares over potential securities laws violations by AMAG Pharmaceuticals was announced and NASDAQ:AMAG stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 02/03/2015 -- An investigation on behalf of investors of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares over potential securities laws violations by AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG and certain of its directors and officers in connection certain financial statements was announced.
Investors who purchased shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) concerning whether certain statements regarding AMAG Pharmaceuticals' business, its prospects and its operations were materially false and misleading at the time they were made.
On June 3, 2014, AMAG Pharmaceuticals, Inc disclosed that on June 2, 2014, AMAG Pharmaceuticals, Inc proposed to the U.S. Food and Drug Administration ("FDA") changes to the current U.S. label of Feraheme Injection based on a review of global post-marketing data.
On January 9, 2015, AMAG Pharmaceuticals, Inc disclosed that on January 7, 2015, after considering AMAG Pharmaceuticals' June 2014 submission and other information, the FDA notified AMAG Pharmaceuticals that it believes new safety information should be included in the labeling of Feraheme, including, among other things, a boxed warning to highlight the risks of serious hypersensitivity/anaphylaxis reactions and revisions that Feraheme should only be administered through an intravenous ("IV") infusion, (i.e., not by IV injection), and should be contraindicated for patients with any known history of drug allergy. The FDA's recommended label changes go beyond what AMAG Pharmaceuticals proposed in June 2014.
AMAG Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $85.38 million in 2012 to $80.86 million and that its respective Net Loss decreased from $16.75 million to $9.60 million. Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) grew from $13.25 per share in May 2012 to as high as $46.94 per share on January 20, 2015.
Those who purchased shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego